This Week in Managed CareThe Top Managed Care News From the First Half of 2019
b'Every week, The American Journal of Managed Care\\xae\\xa0recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.\\n\\nThis week, we recap the top managed care news from the first half of 2019, including outcomes from some of the biggest diabetes trials, research into the annual Medicare wellness visit, and an experimental treatment in Parkinson disease.\\n\\nRead more about the stories in this podcast:\\nMedicare Annual Wellness Visit Association With Healthcare Quality and Costs: https://www.ajmc.com/journals/issue/2019/2019-vol25-n3/medicare-annual-wellness-visit-association-with-healthcare-quality-and-costs\\nCardiovascular Prevention Guidelines Call for Less Aspirin, More SGLT2s, GLP-1s for Type 2 Diabetes: https://www.ajmc.com/conferences/acc-2019/cardiovascular-prevention-guidelines-call-for-less-aspirin-more-sglt2s-glp-1s-for-type-2-diabetes\\nNew Treatment May Have the Potential to Slow, Stop, or Reverse Parkinson Disease: https://www.ajmc.com/newsroom/new-treatment-may-have-the-potential-to-slow-stop-or-reverse-parkinson-disease\\nOral Semaglutide Meets CV Safety Mark, Reduces Events in High-Risk T2D Patients: https://www.ajmc.com/conferences/ada-2019/oral-semaglutide-meets-cv-safety-mark-reduces-events-in-highrisk-t2d-patients\\nNovo Nordisk Seeks Oral Semaglutide Approval, CV Indications on New Drug and Injectable: https://www.ajmc.com/newsroom/novo-nordisk-seeks-oral-semaglutide-approval-cv-indications-on-new-drug-and-injectable-\\nCREDENCE: Canagliflozin Cuts Risk of Renal Failure, Death 30% in Patients With Type 2 Diabetes, CKD: https://www.ajmc.com/newsroom/credence-canagliflozin-cuts-risk-of-renal-failure-death-30-in-patients-with-type-2-diabetes-ckd'